Artelo Biosciences (NASDAQ:ARTL) released its quarterly earnings results on Monday. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.13, Yahoo Finance reports.
NASDAQ:ARTL opened at $1.25 on Tuesday. The stock has a market cap of $4.27 million and a price-to-earnings ratio of -0.78. The company’s 50 day moving average price is $1.32 and its 200-day moving average price is $1.50. Artelo Biosciences has a 52 week low of $0.61 and a 52 week high of $4.42.
In related news, Director Connie Matsui acquired 41,667 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were bought at an average price of $1.27 per share, for a total transaction of $52,917.09. In the last 90 days, insiders have purchased 50,034 shares of company stock worth $63,333. 12.78% of the stock is owned by insiders.
ARTL has been the subject of several recent analyst reports. Maxim Group downgraded shares of Artelo Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, May 13th. ValuEngine upgraded shares of Artelo Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd.
Artelo Biosciences Company Profile
Artelo Biosciences, Inc, an ethical biopharmaceutical company, focuses on developing, licensing, and commercializing cannabinoid therapeutic treatments. Its products pipeline includes ART12.11, a cannabidiol composition for the treatment of inflammatory bowel disease, stroke, and rare/orphan diseases; ART26.12, an endocannabinoid transport protein (FABP5) inhibitor for the treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain; and ART27.13 for the treatment of cancer and cachexia.
Recommended Story: Circuit Breakers
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.